This week, the FDA issued draft guidance to encourage cannabis-related clinical research. We love to see news like this, because we’ve been sponsoring and advocating for veterinary CBD research since the early days of the industry. When everyone else was rushing to slap a cute pet label on a bottle of CBD that might (or might not) contain what the label says it contains, we were out there doing the hard work. Meeting with the scientists and veterinarians at Colorado State University’s College of Veterinary Medicine, sponsoring safety trials and and pharmacokinetics research, and helping to launch Phase 2 efficacy trials for epilepsy and arthritis takes a vast amount of resources, but we’ve been committed from the get-go to doing this right.
Clinical research on the benefits of CBD oil for pets is the reason our company exists. We hear so many stories from our customers about the ways that our CBD oil helps their pets, and we think all those stories deserve to be investigated. That’s why we’re launching a foundation to focus exclusively on raising funds for more research. You’ll hear more from us soon about the foundation, so stay tuned. In the meantime, you can read more about our research and all the veterinary clinical trials here.
As the CBD industry shifts from a “Wild West” mentality to a more regulated and mature industry, the FDA will play an increasing role. Encouraging clinical research—and offering guidelines—is an important step, and one that we welcome. FDA Principal Deputy Commissioner Amy Abernethy M.D., Ph.D described the FDA’s new guidance in a press release issued by the agency:
“A range of stakeholders have expressed interest in development of drugs that contain cannabis and compounds found in cannabis. Recent legislative changes have also opened new opportunities for cannabis clinical research. As that body of research progresses and grows, the FDA is working to support drug development in this area. It is critical that the FDA continues to do what we can to support the science needed to develop new drugs from cannabis. The FDA believes the drug approval process represents the best way to ensure that safe and effective new medicines, including any drugs that contain cannabis or cannabis-derived compounds, are available to patients in need of appropriate medical therapy. It is critical that the FDA continues to do what we can to support the science needed to develop new drugs from cannabis. The FDA believes the drug approval process represents the best way to ensure that safe and effective new medicines, including any drugs that contain cannabis or cannabis-derived compounds, are available to patients in need of appropriate medical therapy.“FDA In Brief: FDA Issues Draft Guidance to Encourage Cannabis-Related Clinical Research, July 21, 2020. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-issues-draft-guidance-encourage-cannabis-related-clinical-research
Three cheers for more FDA involvement in the CBD industry, more accountability from producers, and most importantly, MORE CLINICAL RESEARCH! This is music to our ears.
Want to try to most rigorously researched and tested CBD oil for your pet? Visit the shop, or reach out to email@example.com with any questions!